Actively Recruiting

Phase 1
Age: 21Years - 70Years
All Genders
ID07001930

Pharmacological Effects of Cannabidiol on Responses to Stress and Nicotine Withdrawal

Led by Johns Hopkins University · Updated on 2025-09-02

90

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

J

Johns Hopkins University

Lead Sponsor

N

National Institute on Drug Abuse (NIDA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying how different doses of cannabidiol (CBD) affect stress and nicotine withdrawal symptoms in adults who use nicotine daily. The study focuses on understanding how CBD influences stress responses, tobacco dependence, withdrawal symptoms, and differences between sexes during stress. Participants will be exposed to stress and may be asked to abstain from nicotine for 24 hours to evaluate withdrawal effects. The study uses a double-blind, placebo-controlled, crossover design where each participant receives three doses of CBD (0 mg, 200 mg, and 400 mg) across three separate sessions, each lasting about 5 hours and spaced at least 72 hours apart. Participants are randomly assigned to either continue smoking as usual or abstain from nicotine for 24 hours before each session. The study includes behavioral stress challenges and nicotine withdrawal challenges to assess responses. Participants will attend one medical screening, three phone sessions, and three in-person experimental sessions over 2 to 3 weeks. During sessions, biological samples and subjective reports will be collected at multiple time points to measure mood, cortisol levels, heart rate, blood pressure, and nicotine urges. Various questionnaires and cognitive tests will evaluate pain, cravings, tobacco demand, attention, and reaction times. The study monitors safety and collects detailed data to understand CBD's impact on stress and withdrawal.

CONDITIONS

Brief Title

Effects of Cannabidiol on Stress and Nicotine Withdrawal

Who Can Participate

Age: 21Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy adults aged 21 to 70 years
  • Smoking more than 5 cigarettes daily for over 2 years
  • Biological confirmation of cigarette use with expired carbon monoxide level over 8 ppm
  • Alcohol use less than 2 drinks per day on average (less than 14 drinks per week)
  • Normal nighttime sleep schedule, no graveyard or third shift work
  • Willingness to use effective contraception during the study and for at least 30 days after last study drug if of childbearing potential
Not Eligible

You will not qualify if you...

  • Planning to reduce or quit cannabis or tobacco use within the next 30 days
  • Diagnosed substance use disorder other than alcohol, cannabis, or nicotine
  • Positive test for illicit drugs other than cannabis
  • Positive breath alcohol test at study admission
  • Current physical or mental illness or medication impacting safety or study integrity
  • Resting heart rate over 100 or abnormal blood pressure outside specified ranges
  • Cold intolerance or medical condition worsened by cold exposure
  • Currently pregnant, planning pregnancy within 3 months, or breastfeeding
  • History of significant cardiac arrhythmias or vasospastic diseases
  • History or current liver disease or elevated liver enzymes beyond set limits
  • Enrolled in another clinical trial or received research drug within past 30 days

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 2 to 3 weeks

Participants attend three separate experimental laboratory sessions where they receive different doses of cannabidiol (0mg, 200mg, and 400mg) during exposure to acute stress and nicotine withdrawal challenges.

3 in-person experimental laboratory sessions, each lasting approximately 5 hours and separated by at least 72 hours

Trial Site Locations

Total: 1 location

1

Behavioral Pharmacology Research Unit

Baltimore, Maryland, United States, 21224

Actively Recruiting

Loading map...

Research Team

L

Lauren Brogdon, MHS

D

Dustin C. Lee, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

OTHER

Number of Arms

2

Similar Trials

ACT on Vaping: Digital Therapeutic for Young Adult Vaping Ce...

Nicotine Dependence

Actively Recruiting

1 location

A Feasibility Trial of Eye Movement Desensitization and Repr...

Post Traumatic Stress Symptoms

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here